Over the last 25 years, rapid subcutaneous immunoglobulin (SCIg) infusions have been employed as an essential technique of administering replacement immunoglobulin (Ig) to patients with primary immune deficiencies (PIDs) in Europe. This study offered a detailed analysis of the literature on SCIg administration and the services that were established in tandem. Using rates of at least 20 ml/h per infusion site and simultaneous sites, the infusion period once a week was brief (1–2 h in adults), and the kid or adult was free for other activities during the therapy because compact portable pumps were used. Rapid SCIg infusions were shown to be well-tolerated, effective, and acceptable to newborns and their parents, children, adults, and elderly patients. It was shown more recently in patients with autoimmunity who required immunomodulatory Ig dosages.

Educational programs for self-infusion of intravenous Ig and SCIg at home have been created throughout Europe as part of PID diagnosis and management services, resulting in greater patient compliance and patient empowerment as well as cost savings for healthcare providers.